Literature DB >> 11741215

Receptor-targeted gene delivery via folate-conjugated polyethylenimine.

W Guo1, R L Lee.   

Abstract

A novel synthetic gene tranpan>sfer vector was evaluated for pan> class="Disease">tumor cell-specific targeted gene delivery. The folate receptor is a tumor marker overexpressed in more than 90% of ovarian carcinomas and large percentages of other human tumors. Folic acid is a high affinity ligand for the folate receptor that retains its binding affinity upon derivatization via its gamma carboxyl. Folate conjugation, therefore, presents a potential strategy for tumor-selective targeted gene delivery. In the current study, we investigated a series of folate conjugates of the cationic polymer polyethylenimine (PEI) for potential use in gene delivery. A plasmid containing a luciferase reporter gene (pCMV-Luc) and the folate receptor expressing human oral cancer KB cells were used to monitor gene transfer efficiency in vitro. Transfection activity of polyplexes containing unmodified polyethylenimine was highly dependent on the positive to negative charge (or the N/P) ratio. Folate directly attached to PEI did not significantly alter the transfection activity of its DNA complexes compared to unmodified PEI. Modification of PEI by polyethyleneglycol (PEG) led to a partial inhibition of gene delivery compared to unmodified PEI. Attaching folates to the distal termini of PEG-modified PEI greatly enhanced the transfection activity of the corresponding DNA complexes over the polyplexes containing PEG-modified PEI. The enhancements were observed at all N/P ratios tested and could be blocked partially by co-incubation with 200 microM free folic acid, which suggested the involvement of folate receptor in gene transfer. Targeted vectors based on the folate-PEG-PEI conjugate are potentially useful as simple tumor-specific vehicles of therapeutic genes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11741215      PMCID: PMC2751349          DOI: 10.1208/ps010419

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  22 in total

1.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis.

Authors:  C P Leamon; P S Low
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

2.  99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging.

Authors:  W Guo; G H Hinkle; R J Lee
Journal:  J Nucl Med       Date:  1999-09       Impact factor: 10.057

3.  Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin.

Authors:  G Paganelli; C Belloni; P Magnani; F Zito; A Pasini; I Sassi; M Meroni; M Mariani; M Vignali; A G Siccardi
Journal:  Eur J Nucl Med       Date:  1992

4.  Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer.

Authors:  F Crippa; G Bolis; E Seregni; N Gavoni; G Scarfone; C Ferraris; G L Buraggi; E Bombardieri
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

5.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis.

Authors:  R J Lee; P S Low
Journal:  J Biol Chem       Date:  1994-02-04       Impact factor: 5.157

6.  Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.

Authors:  P Garin-Chesa; I Campbell; P E Saigo; J L Lewis; L J Old; W J Rettig
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

7.  Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.

Authors:  S Wang; R J Lee; G Cauchon; D G Gorenstein; P S Low
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.

Authors:  C F Molthoff; M R Buist; P Kenemans; H M Pinedo; E Boven
Journal:  J Nucl Med       Date:  1992-11       Impact factor: 10.057

9.  Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications.

Authors:  J F Ross; P K Chaudhuri; M Ratnam
Journal:  Cancer       Date:  1994-05-01       Impact factor: 6.860

10.  Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro.

Authors:  R J Lee; P S Low
Journal:  Biochim Biophys Acta       Date:  1995-02-15
View more
  16 in total

1.  Engineering clustered ligand binding into nonviral vectors: alphavbeta3 targeting as an example.

Authors:  Quinn K T Ng; Marie K Sutton; Pan Soonsawad; Li Xing; Holland Cheng; Tatiana Segura
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

2.  Multiplexed supramolecular self-assembly for non-viral gene delivery.

Authors:  Nathan P Gabrielson; Jianjun Cheng
Journal:  Biomaterials       Date:  2010-09-01       Impact factor: 12.479

3.  Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit.

Authors:  Hairong Xiong; Robert J Lee; Eric B Haura; John G Edwards; William S Dynan; Shuyi Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

4.  Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.

Authors:  Kathrin Klutz; Michael J Willhauck; Christian Dohmen; Nathalie Wunderlich; Kerstin Knoop; Christian Zach; Reingard Senekowitsch-Schmidtke; Franz-Josef Gildehaus; Sibylle Ziegler; Sebastian Fürst; Burkhard Göke; Ernst Wagner; Manfred Ogris; Christine Spitzweg
Journal:  Hum Gene Ther       Date:  2011-10-11       Impact factor: 5.695

5.  Synthesis, characterization, and in vitro assay of folic acid conjugates of 3'-azido-3'-deoxythymidine (AZT): toward targeted AZT based anticancer therapeutics.

Authors:  Anthony R Vortherms; Robert P Doyle; Dayuan Gao; Olivia Debrah; Patrick J Sinko
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-02       Impact factor: 1.381

6.  The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice.

Authors:  Klaus Kunath; Anke von Harpe; Holger Petersen; Dagmar Fischer; Karlheinz Voigt; Thomas Kissel; Ulrich Bickel
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

7.  Riboflavin-targeted polymer conjugates for breast tumor delivery.

Authors:  Lisa M Bareford; Brittany R Avaritt; Hamidreza Ghandehari; Anjan Nan; Peter W Swaan
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

8.  Combining Stimulus-Triggered Release and Active Targeting Strategies Improves Cytotoxicity of Cytochrome c Nanoparticles in Tumor Cells.

Authors:  Moraima Morales-Cruz; Alejandra Cruz-Montañez; Cindy M Figueroa; Tania González-Robles; Josue Davila; Mikhail Inyushin; Sergio A Loza-Rosas; Anna M Molina; Laura Muñoz-Perez; Lilia Y Kucheryavykh; Arthur D Tinoco; Kai Griebenow
Journal:  Mol Pharm       Date:  2016-06-27       Impact factor: 4.939

9.  Receptor-mediated gene delivery by folic acid-modified stearic acid-grafted chitosan micelles.

Authors:  Yong-Zhong Du; Li-Li Cai; Jin Li; Meng-Dan Zhao; Feng-Ying Chen; Hong Yuan; Fu-Qiang Hu
Journal:  Int J Nanomedicine       Date:  2011-08-01

10.  Process optimization for the preparation of oligomycin-loaded folate-conjugated chitosan nanoparticles as a tumor-targeted drug delivery system using a two-level factorial design method.

Authors:  Yuangang Zu; Qi Zhao; Xiuhua Zhao; Shuchong Zu; Li Meng
Journal:  Int J Nanomedicine       Date:  2011-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.